SynthesisMedicine2018
Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis.
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Assessment on clinical value of prostate health index in the diagnosis of prostate cancer.Cancer medicine · 2019Pooled it
- Diagnostic performance of magnetic resonance imaging-targeted biopsy for PI-RADS ≥3 peripheral zone lesions in multiparametric prostate magnetic resonance imaging: correlation with clinically significant prostate cancer.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Correlating Histological Results and Total Serum Levels of the Prostate-Specific Antigen Among Patients in Southwestern Uganda.Prostate cancer · 2026Article
- Serum PSA levels fluctuations in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy: a prospective study.BMC urology · 2025Article
- Review
- The association between urinary nitrate and prostate specific antigen without prostatic disease: a cohort study.BMC urology · 2025Article
- Usefulness of free PSA ratio to enhance detection of clinically significant prostate cancer in patients with PI-RADS<3 and PSA≤10.Prostate international · 2025Article
- Comparison of prostate cancer detection rates and complications between transrectal ultrasound-guided transperineal and transrectal biopsies: a systematic review and meta-analysis.Translational andrology and urology · 2025Article
- Dual-Enhanced SERS Satellite Immuno-Nanocomplex for Multiple PSA-Mediated PHI Assay Toward Clinical Prostate Cancer Screening.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Comparison of PSA Values from capillary dried blood spot analysis and venous serum samples.PloS one · 2025Article
- Diagnostic accuracy of PSA derivatives for prostate cancer in patients with low prostate-specific antigen levels.Frontiers in oncology · 2025Article
- Prostate cancer theragnostics biomarkers: An update.Investigative and clinical urology · 2024Review
- Prostate cancer with elevated free prostate-specific antigen density: A case report.World journal of clinical cases · 2024Article
- Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays.European urology open science · 2024Article
- Article
- Clinical assessment of TGFB1 and HP Relative Gene Expression in the Peripheral Blood of Prostate Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging.American journal of cancer research · 2024Article
- Advances in Prostate Cancer Biomarkers and Probes.Cyborg and bionic systems (Washington, D.C.) · 2024Review
- Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer.Irish journal of medical science · 2023Article
- Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study.Translational andrology and urology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate carcinoma is a common disease that occurs in men over 50 years old. Many studies have explored the effect of free/total prostate-specific antigen (f/t PSA) ratio in monitoring prostate cancer. We conducted a meta-analysis to identify the accuracy of the f/t PSA ratio in the diagnosis of prostate cancer in patients who have PSA levels of 4 to 10 ng/mL.
methodsDatabases searched included PubMed and OVID databases, from inception to March 2017, after a systematical review, sensitivity, specificity, and other measures of accuracy of the f/t PSA ratio in the diagnosis of prostate cancer were pooled. We used summary receiver operating characteristic curves to summarize overall test performance.
resultsFifteen case-control studies from 14 articles were identified. The results indicated that the sensitivity of the f/t PSA ratio in the diagnosis of prostate cancer ranged from 0.5 to 0.94 (pooled sensitivity 0.70, 95% CI: 0.67-0.72), whereas its specificity ranged from 0.31 to 0.93 (pooled specificity 0.55, 95% CI: 0.57-0.60). The positive likelihood ratio was 1.85 (95% CI: 1.56-2.20), negative likelihood ratio was 0.42 (95% CI: 0.34-0.53), and diagnostic odds ratio was 4.81 (9.53% CI: 3.33-6.94).
conclusionsThe f/t PSA ratio determination has a low sensitivity and specificity for the diagnosis of prostate cancer; it would not be useful for the diagnosis of prostate cancer by itself. The results of f/t PSA ratio measurements should refer to the clinical manifestations and the results of conventional tests such as biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.